Grounded in two decades of drug mechanism research.
Leveraging insights from widely used medicines like rapamycin, metformin, bisphosphonates, and antidepressants, BIOIO was founded on over twenty years of research into how drugs work. This extensive knowledge allowed us to define a gold standard for Mechanism of Action (MoA) elucidation, leading to the creation of our genetics-based MOAT platform.
As our process continues to evolve, we’ve increasingly incorporated big data and automation, believing these advancements are key to accelerating drug development. Our experts have also embraced in silico technology to virtually replicate our wet-lab processes, further enhancing the precision and scalability of our approach.
Dr. Peterson trained @ MIT and Harvard in two HHMI labs. Previously, Assistant Professor at Washington University School of Medicine (WashU).
Trained @ Netherlands Cancer Institute (NKI). Previously BD at the longevity company Rejuveron Life Sciences and biologics manufacturer Batavia Biosciences.
BIOIO-2001 lead. Associate Professor @ WashU. 7 INDs. Director of WashU’s Center for Drug Discovery.
Professor of Medicine UT Southwestern. GLP-1RA pioneering clinical trialist.
BIOIO-1xx1 lead. Inventor of BIOIO-1001, 10+ years experience in this chemical class. Ex-Pfizer and Pfizer acquired companies.
Cumulus Oncology, Former Exec VP and CSO of Fresenius group.
Assistant Professor @ Yale. Co-founder Meliora Therapeutics. MoA Analysis.
CSO, Aclaris Therapeutics. Previously, Pfizer Executive Director R&D. St. Louis company building advice.
